Evaluation of core and symbolic capabilities during due-diligence processes in new biotechnology firms

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

ملخص

This study discusses the role of core and symbolic capabilities during due-diligence processes when investing in companies in turbulent fields such as the biotechnology industry. The results indicate that investors' evaluations are hierarchical and are based on two premises. First, investors look for core capabilities - the characteristics that signal the potential for future success. They then search for symbolic elements, such as reputation, to confirm their decisions. The study expands earlier models of investors' evaluation processes. It also offers new insights for entrepreneurs of biotechnology firms.

اللغة الأصليةالإنجليزيّة
رقم المقال1450043
دوريةInternational Journal of Innovation and Technology Management
مستوى الصوت11
رقم الإصدار6
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - 22 ديسمبر 2014
منشور خارجيًانعم

All Science Journal Classification (ASJC) codes

  • !!Management of Technology and Innovation

بصمة

أدرس بدقة موضوعات البحث “Evaluation of core and symbolic capabilities during due-diligence processes in new biotechnology firms'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا